Vertex to advance VX-147 for kidney disease into pivotal trial
Rasi Bhadramani/iStock via Getty Images


Vertex Pharmaceuticals (VRTX -0.3%) will advance VX-147 for proteinuric kidney disease into a phase 2/3 trial with enrollment beginning later this month.
The primary endpoint is reduction in the rate of decline of kidney function as measured by estimated glomerular filtration rate (eGFR) slope versus placebo at approximately two years.

At week 48, a pre-planned interim analysis will also be conducted.
Vertex (NASDAQ:VRTX) said if the results at this point are positive, it will serve as the basis to seek accelerated approval.
VX-147 is specifically for people with proteinuric kidney disease mediated by two mutations in the APOL1 gene, which impacts ~100K people in the U.S. and Europe.
Read why Seeking Alpha contributor Denis Buivolov argues that Vertex (VRTX -0.3%) is a buy.